Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote & News

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 264 4280

Fax: 857 264 4299

Website: rhythmtx.com

Address:

222 Berkeley Street, 12th Floor, Boston, United States

abcdzepeda Aug. 24 at 7:25 PM

$RYTM Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- let’s gooooooo! Hopefully this starts moving us upward tomorrow!

0 · Reply

SportTrade Aug. 21 at 3:36 PM

$PTN keep an eye on this one! Been a painful newsflow vacuum but we now approaching potential catalyst rich setup again so I think the SP can recover lost ground and quickly as interest grows again. Most immediately we saw smart HC specialists buy in per 13Fs including new positions albeit small from woodline and Opaleye and big boys Janus, logos, augc, RA, Sirenia all still top holders. Next reporting is September and November I believe and all important opening of the IND which they guided to filing in Q4 so that could happen as soon as October. Meanwhile $RYTM trades at $7.5-$8B on strong commercial momentum from older gen Mc4r asset with daily dosing burden. Once PTN files for their differentiated once weekly version w even better pot’l tolerability profile… I think new funds jump in as PTN officially be 30 days out from being ckincical stage company… then the investment case is really simple: hey $SLNO bot for $3B/ this is potential mini RYTM so valuation gap should close! GLTA

3 · Reply

Doozio Aug. 20 at 4:42 PM

$QQQ in $HRMY n $RYTM then it’s ONTO or ENTA 🐒🍌🧠⏰♾️

0 · Reply

Doozio Aug. 20 at 2:32 PM

If it is then this should be the 🎁 in $HRMY N FRYday da 🧠 gets back in $RYTM

1 · Reply

Doozio Aug. 19 at 1:06 AM

da huckleberries are below da $$$$ and soon da 🧠 shud be back in $RYTM out of the tightness if only they gave YO a sign in $HRMY while da 🐑 are Semi worried about AI stonks that 🐑 term stink.

0 · Reply

biolover Aug. 18 at 8:45 PM

$AMLX $VKTX rip off. Look at $RYTM drug price Welcome to the woke health system

0 · Reply

Stonky_Mcprofitface Aug. 14 at 10:33 AM

$RYTM Friday bloodbath?

0 · Reply

Stonky_Mcprofitface Aug. 13 at 12:46 AM

$RYTM uh huh.

1 · Reply

CharlieeMungerTWITS Aug. 12 at 6:40 PM

$RYTM

0 · Reply

wizeinvesting Aug. 12 at 8:30 AM

$SPCX $RYTM $MSFT $AMZN $NVDA SpaceX has already reached a staggering $1.75 trillion valuation, making the question of future upside far more complicated than simply betting on rockets or Starlink. The bigger opportunity—and risk—may now come from its rapidly expanding AI infrastructure business, where billions of dollars in compute capacity could transform the company into something far larger than a space and satellite business. For long-term investors, the real challenge is determining whether SpaceX can grow fast enough, execute its... https://www.wizeinvesting.com/p/rytm-s-734-climb-what-steady-500-investing-could-build

0 · Reply

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Aug 17, 2026, 8:00 AM EDT - 7 days ago

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Aug 12, 2026, 9:00 AM EDT - 12 days ago

Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-05T14:28:47.000Z - 19 days ago

Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital

2026-08-05T11:21:19.000Z - 19 days ago

Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord

2026-08-05T10:40:31.000Z - 19 days ago

Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi

2026-08-05T09:50:16.000Z - 19 days ago

Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens

Aug 4, 2026, 4:01 PM EDT - 20 days ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Aug 4, 2026, 8:30 AM EDT - 20 days ago

Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition

Aug 4, 2026, 8:00 AM EDT - 20 days ago

Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 20 days ago

Rhythm Pharmaceuticals Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 20 days ago

Rhythm Pharmaceuticals Slides: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 20 days ago

Rhythm Pharmaceuticals Quarterly report: Q2 2026

2026-08-04T11:16:07.000Z - 20 days ago

Rhythm Pharmaceuticals’ RM-718 shows efficacy in Phase 2 obesity trial

Aug 4, 2026, 7:01 AM EDT - 20 days ago

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Aug 4, 2026, 6:55 AM EDT - 20 days ago

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

2026-07-27T09:10:19.000Z - 4 weeks ago

Rhythm Pharmaceuticals initiated with an Overweight at JPMorgan

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Jul 8, 2026, 5:07 PM EDT - 6 weeks ago

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

2026-07-07T11:35:29.000Z - 6 weeks ago

Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital

2026-06-16T10:50:36.000Z - 2 months ago

Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord

Jun 15, 2026, 4:01 PM EDT - 2 months ago

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

2026-06-15T10:35:32.000Z - 2 months ago

Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo

2026-06-14T20:35:33.000Z - 2 months ago

Rhythm announces preliminary data from Phase 2 trial of setmelanotide

Jun 13, 2026, 9:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Transcript: Study result

Jun 13, 2026, 9:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Slides: Study result

Jun 13, 2026, 9:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Press release: Study result

Jun 13, 2026, 8:01 AM EDT - 2 months ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

PWS

Jun 12, 2026, 4:01 PM EDT - 2 months ago

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

PWS

Jun 8, 2026, 1:20 PM EDT - 2 months ago

Rhythm Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 12:50 PM EDT - 2 months ago

Rhythm Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 29, 2026, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

May 29, 2026, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

May 26, 2026, 7:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Slides: Corporate presentation

May 13, 2026, 6:00 PM EDT - 3 months ago

Rhythm Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology

2026-05-07T16:30:44.000Z - 3 months ago